Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tolerability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,038 result(s) found for: Tolerability. Displaying page 151 of 702.
    «« First « Previous 147  148  149  150  151  152  153  154  155  Next» Last»»
    EudraCT Number: 2007-005088-82 Sponsor Protocol Number: CAFQ056A2204 Start Date*: 2008-05-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of mul...
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017324 Fragile X syndrome PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004002-25 Sponsor Protocol Number: B1621007 Start Date*: 2012-01-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND SITAGLIPTIN ON GLYCEMIC CONTROL IN ADULT PATIENTS WI...
    Medical condition: Type 2 Diabetes Mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000250-28 Sponsor Protocol Number: 905-CL-079 Start Date*: 2011-11-15
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10012547 Detrusor hyperreflexia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000128-16 Sponsor Protocol Number: 2011-003 Start Date*: 2012-07-30
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005675-15 Sponsor Protocol Number: DIL-UBI-DEX-CLOII/2003/003/PT Start Date*: 2008-10-08
    Sponsor Name:Tecnimede, Sociedade Técnico-Medicinal S.A.
    Full Title: Randomized, multicenter, placebo-controlled, single blind study to assess the efficacy and tolerability of a combination of a cream containing ubidecarenone, dexpanthenol and chlorohexidine and a p...
    Medical condition: Cronic Anal fissure (CAF) The underlying pathogenesis of chronic anal fissure involves initial local trauma (generally caused by hard stools), resulting in a wound, internal anal sphincter spasm an...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10071195 Chronic anal fissure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-006294-26 Sponsor Protocol Number: 021101 Start Date*: 2013-04-07
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A Phase 3, Prospective, Open-label, Randomized Study to Evaluate Safety and Efficacy of Recombinant Activated FVII BI (rFVIIa BI) in the Treatment of Acute Bleeding Episodes per an On-demand Regime...
    Medical condition: Hemophilia A or B with FVIII or FIX inhibitors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    14.1 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: ES (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004786-40 Sponsor Protocol Number: PB-102-F01 Start Date*: 2013-05-10
    Sponsor Name:Protalix Ltd.
    Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000821-37 Sponsor Protocol Number: GS-US-416-2124 Start Date*: 2017-02-06
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic H...
    Medical condition: Alcoholic Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001496-75 Sponsor Protocol Number: GS-US-379-1582 Start Date*: 2016-12-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid Arthritis on...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003417-95 Sponsor Protocol Number: 201247 Start Date*: 2017-01-13
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, randomized, double-blind (sponsor open), placebo controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explo...
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003585-11 Sponsor Protocol Number: VX16-659-101 Start Date*: 2017-09-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005021-39 Sponsor Protocol Number: CAIN457F2308 Start Date*: 2016-08-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab in prefilled syringes, to compare efficacy at 16 weeks with placebo and to assess safety and ...
    Medical condition: Ankylosing Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-005980-27 Sponsor Protocol Number: NK-104-308 Start Date*: 2006-05-04
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: OPEN-LABEL, LONG-TERM ( ≥ 1 YEAR) EXTENSION STUDY OF PITAVASTATIN 2 MG AND 4 MG QD IN ELDERLY PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
    Medical condition: Patients with Primary Hypercholesterolemia or Combined Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005721-30 Sponsor Protocol Number: 161HF201 Start Date*: 2009-10-26
    Sponsor Name:Biogen Idec
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency
    Medical condition: Heart Failure and Renal Insufficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038474 Renal insufficiency LLT
    9.1 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002287-11 Sponsor Protocol Number: BAY1021189/15371 Start Date*: 2013-12-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) DE (Completed) ES (Completed) NL (Completed) HU (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002288-25 Sponsor Protocol Number: BAY1021189/15829 Start Date*: 2013-12-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) NL (Completed) ES (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005619-18 Sponsor Protocol Number: Calcichew-4001 Start Date*: 2015-05-05
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Randomized, Open-Label, 2-Way Cross-over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D ...
    Medical condition: Prevention and treatment of vitamin D and calcium deficiency and adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10031289 Osteoporosis, unspecified LLT
    18.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002208-26 Sponsor Protocol Number: MK-8342B-062 Start Date*: 2015-10-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.
    Full Title: A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17β-estradiol) vaginal ring and the levonorgestrel-...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed) SE (Completed) DE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) HU (Completed) PL (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004902-13 Sponsor Protocol Number: D0490C00023 Start Date*: 2015-04-09
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positr...
    Medical condition: Multiple system atrophy (MSA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002156-84 Sponsor Protocol Number: 63623872FLZ3001 Start Date*: 2018-05-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, a...
    Medical condition: Influenza A Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 147  148  149  150  151  152  153  154  155  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Sep 03 21:18:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA